## 2 Results and Discussion
### Distribution of ARR VOCs In Vivo in Rats
#### 2.2.1 Distribution of VOCs in ARR Powder-Treated Group
\begin{table}
\begin{tabular}{r r r r r r r r r r r r r r r r r r r r} \hline \multicolumn{13}{c}{**3-S-Dimethohydroluence**} & \multicolumn{3}{c}{**Safrite**} & \multicolumn{3}{c}{**Methodytegenol**} & \multicolumn{3}{c}{**23,3-Trimethohydroluence**} & \multicolumn{3}{c}{**3,4-S-Trimethohydroluence**} & \multicolumn{3}{c}{**Egenel**} & \multicolumn{3}{c}{**Kalouol**} \\  & \multicolumn{3}{c}{**(M69)**} & \multicolumn{3}{c}{**(M66)**} & \multicolumn{3}{c}{**(M79)**} & \multicolumn{3}{c}{**(M82)**} & \multicolumn{3}{c}{**(M83)**} & \multicolumn{3}{c}{**(M83)**} & \multicolumn{3}{c}{**(M93)**} & \multicolumn{3}{c}{**(M138)**} \\ \hline  & **P** & **D** & **Ratio** & **P** & **D** & **Ratio** & **P** & **D** & **Ratio** & **P** & **D** & **Ratio** & **P** & **D** & **Ratio** & **P** & **D** & **Ratio** & **P** & **D** & **Ratio** \\ \hline FE & 7.19 & n.d. & / & 3.25 & 0.0058 & 560.3 & 2.04 & 0.0052 & 392.3 & 3.45 & 0.005 & 690.0 & 4.07 & 0.01 & 407.0 & 0.10 & 0.02 & 5.4 & 1.36 & 0.70 & 1.9 \\ UR & 0.54 & n.d. & / & 0.04 & 0.0038 & 10.5 & 0.12 & 0.0064 & 18.8 & 0.65 & 0.030 & 21.7 & 1.10 & 0.32 & 3.4 & 5.66 & 6.58 & 0.9 & 16.79 & 10.51 & 1.6 \\ BL & 2.68 & n.d. & / & 2.54 & n.d. & / & 0.5 & n.d. & / & 1.91 & 0.032 & 99.7 & 2.11 & 0.31 & 6.8 & n.d. & n.d. & / & 0.10 & 0.02 & 6.4 \\ BR & 2.48 & n.d. & / & 1.94 & n.d. & / & 0.4 & n.d. & / & 0.75 & 0.007 & 107.1 & 0.64 & 0.06 & 10.7 & n.d. & n.d. & / & 0.07 & 0.01 & 13.0 \\ HE & 1.45 & n.d. & / & 0.98 & n.d. & / & 0.26 & n.d. & / & 0.54 & 0.007 & 77.1 & 0.46 & 0.05 & 9.2 & n.d. & 0.04 & 7.06 & 0.05 & 12.5 \\ LU & 1.27 & n.d. & / & 0.98 & n.d. & / & 0.24 & n.d. & / & 0.39 & 0.008 & 48.8 & 0.33 & 0.05 & 6.6 & 0.05 & 0.01 & 5.2 & 0.09 & 0.01 & 10.9 \\ SP & 1.36 & n.d. & / & 1.43 & 0.004 & 357.5 & 0.9 & 0.0016 & 562.5 & 0.97 & 0.009 & 107.8 & 0.59 & 0.06 & 9.8 & 0.02 & 0.01 & 3.0 & 0.16 & 0.01 & 21.7 \\ I & 7.09 & 0.0017 & 477.0 & 5.03 & 0.0012 & 401.79 & 1.29 & 0.0032 & 402.1 & 2.26 & 0.031 & 72.9 & 1.89 & 0.24 & 7.9 & 0.05 & 0.02 & 2.6 & 0.05 & 0.04 & 1.2 \\ KI & 4.63 & 0.019 & 2463.6 & 2.48 & 0.0018 & 137.78 & 0.88 & 0.0051 & 172.5 & 2.58 & 0.056 & 46.1 & 2.78 & 0.56 & 5.0 & 0.22 & 0.23 & 0.9 & 1.13 & 0.31 & 3.6 \\ ST & 35.16 & 0.0025 & 2046.0 & 45.64 & n.d. & / & 34.99 & 0.0801 & 456.8 & 18.84 & 0.293 & 64.3 & 17.07 & 1.90 & 9.0 & 0.20 & 0.05 & 4.1 & 8.58 & 2.36 & 3.6 \\ IN & 13.06 & 0.0021 & 6219.0 & 16.62 & 0.0025 & 6480.0 & 12.38 & 0.0069 & 1794.2 & 6.56 & 0.026 & 252.3 & 5.83 & 0.13 & 44.8 & 0.06 & 0.12 & 0.5 & 2.01 & 0.22 & 9.2 \\ \hline \multicolumn{13}{l}{P; powder-treated group; D; Accretion-treated group; FE: feces; UR: urine; BL: blood; BR: brain; HE: heart; LU: lung; SP: spleen; IL: liver; KI: kidney; SI: stomach; IN: small intestine. Ratice the ratio of peak areas between powder- and detection-treated groups. n.d.: not detected. /: The ratio cannot be calculated because the constituents failed to be detected: on the powder- or detection-treated group.} \\ \end{tabular}
\end{table} 
Table 4: Peak areas of main absorbed constituents and their ratio between different administration groups (\(\times\)10\({}^{\prime\prime}\)).